Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.63 |
| ▸ | BCL6 | P41182 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 3/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2101820 | 0.92 | BCL6 (0.55) | SYKBCL6BRD4NPC1RAB9A | |
| SCHEMBL2103244 | 0.83 | SYK (0.67) | SYKBCL6BRD4AURKAEGFR | |
| SCHEMBL2102001 | 0.81 | BCL6 (0.71) | SYKBCL6AURKA | |
| SCHEMBL2101292 | 0.81 | BCL6 (0.61) | SYKBCL6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL656736 | 0.77 | SYK (1.00) | SYKAURKAEGFR | |
| SCHEMBL31294190 | 0.77 | SYK (1.00) | SYKAURKAEGFR | |
| SCHEMBL2104446 | 0.77 | SYK (0.66) | SYKBCL6AURKAEGFR | |
| SCHEMBL13025358 | 0.77 | SYK (0.66) | SYKBRD4AURKAAURKBCCNT1 | |
| SCHEMBL3447633 | 0.77 | NPC1 (0.59) | BRD4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL656237 | 0.76 | SYK (0.60) | SYKBCL6BRD4AURKAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2130541-A2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |